drugset / Trial / NCT00338338

The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients

NCT00338338

Phase 4 Completed 70 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The sustained reduction in elevated blood pressure and lower incidence of adverse events of Lacidipine may provide additional benefits for hypertension patients than other CCBs (calcium channel blockers). This study is to compare the efficacy and safety of Lacidipine with Amlodipine, the most widely used CCB in Taiwan, in hypertensive patients.

Timeline

Start
2005-11-07
Primary completion
2007-09-14
Completion
2007-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Amlodipine Other / unclassified 10 mg Oral
Subject Lacidipine Small molecule 4 mg Oral
Subject Lacidipine Small molecule 6 mg Oral